Abnormal glutathione and sulfate levels after interleukin 6 treatment and in tumor-induced cachexia.
Excessive urea excretion associated with a negative nitrogen balance and massive loss of skeletal muscle mass (cachexia) is a frequent life threatening complication in malignancies and HIV infection. As these patients have often elevated interleukin-6 (IL-6) and abnormally low cystine levels, we have now determined the intracellular levels of glutathione and other cysteine derivatives in the liver and muscle tissue of IL-6-treated or tumor-bearing C57BL/6 mice. IL-6 treatment or inoculation of the MCA-105 fibrosarcoma caused a significant increase in hepatic gamma-glutamyl-cysteine synthetase activity and a decrease in the sulfate level, glutamine/urea ratio, and glutamine/glutamate ratio, suggesting that a decrease of the proton generating cysteine catabolism in the liver may increase carbamoyl-phosphate synthesis and urea formation at the expense of net glutamine synthesis. Treatment with cysteine, conversely, caused an increase in sulfate, glutamine/urea ratios, and glutamine/glutamate ratios and may thus be a useful therapeutic tool in clinical medicine. In contrast to the liver, muscle tissue of tumor-bearing mice showed decreased glutathione and increased sulfate levels, suggesting that the cysteine pool may be drained by an increased cysteine catabolism in this tissue. The findings indicate that tumor cachexia is triggered initially by IL-6 and is later sustained by processes driven by an abnormal cysteine metabolism in different organs.-Hack, V., Gross, A., Kinscherf, R., Bockstette, M., Fiers, W., Berke, G., and Dröge, W. Abnormal glutathione and sulfate levels after interleukin 6 treatment and in tumor-induced cachexia.
Hack
V
V
Division of Immunochemistry, Deutsches Krebsforschungszentrum, Heidelberg, Germany.
Gross
A
A
Kinscherf
R
R
Bockstette
M
M
Fiers
W
W
Berke
G
G
Dröge
W
W
D000818:Animals; D002100:Cachexia / Q000209:etiology / Q000378:metabolism*; D003545:Cysteine / Q000494:pharmacology; D005260:Female; D005354:Fibrosarcoma / Q000150:complications; D005721:Glutamate-Cysteine Ligase / Q000378:metabolism; D005978:Glutathione / Q000378:metabolism*; D015850:Interleukin-6 / Q000494:pharmacology*; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000150:complications*; D013431:Sulfates / Q000378:metabolism*; D014407:Tumor Cells, Cultured; D014508:Urea / Q000378:metabolism
D015850:Interleukin-6; D013431:Sulfates; D014508:Urea; D005721:Glutamate-Cysteine Ligase; D005978:Glutathione; D003545:Cysteine